SLC22A17 and myeloproliferative neoplasm: - SLC22A17 showed opposite expression to LCN2 in serial samples (prior or after IT) of PBMCs in MPN patients- High BCR-ABL transcript (sign of CML) levels are associated with low SLC22A17, but high LCN2 expression